EZH2 and glioblastoma: These data indicated that miR-101 reversed the hypermethylation of LRRC4 promoter and induced the re-expression of LRRC4 in GBM cells by directly targeting EZH2, EED, and DNMT3A to decrease H3K27me3 enrichment of the LRRC4 core promoter.